Chemical chaperone therapy for GM1-gangliosidosis |
| |
Authors: | Y Suzuki |
| |
Institution: | (1) International University of Health and Welfare Graduate School, 2600-1 Kita-Kanemaru, Otawara 324-8501, Japan |
| |
Abstract: | We have proposed a chemical chaperone therapy for lysosomal diseases, based on a paradoxical phenomenon that an exogenous
competitive inhibitor of low molecular weight stabilizes the target mutant molecule and restores its catalytic activity as
a molecular chaperone intracellularly. After Fabry disease experiments, we investigated a new synthetic chaperone compound
N-octyl-4-epi-β-valienamine (NOEV) in a GM1-gangliosidosis model mice. Orally administered NOEV entered the brain through the blood-brain barrier, enhanced β-galactosidase
activity, reduced the substrate storage, and clinically improved neurological deterioration. We hope that chemical chaperone
therapy will prove useful for some patients with GM1-gangliosidosis and potentially other lysosomal storage diseases with central nervous system involvement.
Received 10 October 2007; received after revision 31 October 2007; accepted 6 November 2007 |
| |
Keywords: | Chemical chaperone therapy GM1-gangliosidosis β -galactosidase N-octyl-4-epi-β -valienamine neurogenetic disease |
本文献已被 PubMed SpringerLink 等数据库收录! |
|